Who are Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): efalizumab plus acitretin, Dapsone; Tretinoin, Minocycline plus tretinoin, Duobrii®, Etanercept + Acitretin, Duobrii 0.01 % / 0.045 % Topical Lotion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adapalene-gel-0-1-tazarotene-cream-0-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% (Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid combination. Area: Dermatology.

marketed Retinoid combination Retinoic acid receptors (RAR-α, RAR-β, RAR-γ) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% (Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%) — Galderma R&D. This combination product delivers two retinoid receptor agonists that normalize skin cell differentiation and reduce inflammation to treat acne and photoaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% TARGET	Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%	Galderma R&D	marketed	Retinoid combination	Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)
efalizumab plus acitretin	efalizumab plus acitretin	Universita di Verona	marketed	Monoclonal antibody + retinoid combination	CD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR)
Dapsone; Tretinoin	Dapsone; Tretinoin	Allergan	marketed	Antimicrobial/retinoid combination
Minocycline plus tretinoin	Minocycline plus tretinoin	Derm Research @ 888 Inc.	marketed	Tetracycline antibiotic + retinoid combination	Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin)
Duobrii®	Duobrii®	Icahn School of Medicine at Mount Sinai	marketed	Topical corticosteroid and retinoid combination	Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)
Etanercept + Acitretin	Etanercept + Acitretin	Pfizer	marketed	TNF inhibitor + retinoid combination	TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR)
Duobrii 0.01 % / 0.045 % Topical Lotion	Duobrii 0.01 % / 0.045 % Topical Lotion	Austin Institute for Clinical Research	phase 3	Topical corticosteroid + retinoid combination	Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Retinoid combination class)

Galderma R&D · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% — Competitive Intelligence Brief. https://druglandscape.com/ci/adapalene-gel-0-1-tazarotene-cream-0-1. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab